三阴性乳腺癌的耐药机制及与DLG5的研究进展  

Drug Resistance Mechanism of Tri-ple-Negative Breast Cancer and Research Progress with DLG5

作　　者：王旭升 陈波 车景敏 王虎霞 徐翠香[2] 宋张骏 

机构地区：[1]西安医学院研究生工作部,陕西 西安 [2]陕西省人民医院感染与免疫疾病重点实验,陕西 西安 [3]陕西省肿瘤医院乳腺病院,陕西 西安 [4]陕西省人民医院肿瘤外科,陕西 西安

出　　处：《临床医学进展》2023年第11期18067-18076,共10页Advances in Clinical Medicine

摘　　要：三阴性乳腺癌(Triple Negative Breast Cancer, TNBC)是乳腺癌的一种特定亚型,因其不表达雌激素受体 (Estrogen Receptor, ER)、孕酮受体(Progesterone Receptor, PR)或人表皮生长因子受体-2 (Epi-dermal Growth Factor Receptor, HER-2)具有高侵袭能力,预后较其他类型乳腺癌差,在治疗上往往因为出现耐药性导致癌症进展和复发。早期应用化疗药物对三阴性乳腺癌有明显治疗效果,但随着化疗药物的应用,患者可逐渐出现耐药,导致总体生存率低下。因此,研究三阴性乳腺癌的化疗耐药性是目前乳腺癌的关注热点。本文回顾了三阴性乳腺癌耐药的研究进展,特别是极性蛋白DLG5在三阴性乳腺癌耐药中的作用以及影响,以期为临床治疗提供参考。Triple negative breast cancer (TNBC) is a specific subtype of breast cancer because it does not ex-press estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor re-ceptor (epidermal growth factor receptor, HER-2) has high aggressiveness, has a worse prognosis than other types of breast cancer, and is often treated because of drug resistance leading to cancer progression and recurrence. Early use of chemotherapy drugs has a significant therapeutic effect on triple-negative breast cancer, but with the application of chemotherapy drugs, patients can gradu-ally develop drug resistance, resulting in low overall survival. Therefore, the study of chemotherapy resistance in triple-negative breast cancer is currently a hot spot in breast cancer. This article re-views the research progress of triple-negative breast cancer drug resistance, especially the role and impact of polar protein DLG5 in triple-negative breast cancer drug resistance, in order to provide reference for clinical treatment.

关 键 词：三阴性乳腺癌 DLG5 耐药机制 

分 类 号：R73[医药卫生—肿瘤]